AIHTA - Publications - Search - Selpercatinib (Retsevmo®) for the treatment of RET-fusion positive NSCLC, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer

Grössmann, N. (2020): Selpercatinib (Retsevmo®) for the treatment of RET-fusion positive NSCLC, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer. Oncology Fact Sheet Nr. 36.

[thumbnail of Oncology Fact Sheet Nr.36.pdf]
Preview
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
87kB

Item Type:Oncology Fact Sheet
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WK Endocrine system > WK 200-300 Thyroid gland. Parathyroid gland
Language:English
Series Name:Oncology Fact Sheet Nr. 36
Deposited on:04 Jan 2021 14:13
Last Modified:04 Jan 2021 16:33

Repository Staff Only: item control page